Povara bolii ficatului steatozic

Felicia Darii; Olga Tagadiuc

doi:10.52673/18570461.24.2-73.09

Autori

Felicia Darii Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău https://orcid.org/0000-0002-5993-548X
Olga Tagadiuc Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău https://orcid.org/0000-0002-5503-8052

DOI:

https://doi.org/10.52673/18570461.24.2-73.09

Cuvinte cheie:

boala ficatului steatozic, obezitate, diabet zaharat

Rezumat

Boala ficatului steatozic reprezintă una dintre cele mai frecvente etiologii ale bolilor hepatice cronice, în special în ţările dezvoltate. Ea este în corelație directă cu prevalența sindromului metabolic şi a stilului de viaţă occidental. Astfel, ne-am propus să studiem impactul bolii ficatului gras la nivel global, în funcție de răspândirea geografică, vârstă, sex și factorii de risc asociați, utilizând literatura de specialitate, bazele de date PubMed și Google Scholar. A fost observat faptul că boala ficatului steatozic reprezintă o patologie cu răspândire globală, întâlnită mai frecvent la bărbați și femei în post-menopauză, sugerând rolul protector al hormonilor sexuali feminini. De asemenea, boala ficatului steatozic este considerată manifestarea hepatică a sindromului metabolic, fiind diagnosticată frecvent în rândul pacienților cu diabet zaharat tip 2 și/sau obezitate. Incidența crescută a bolii a fost remarcată și în rândul copiilor, adolescenților supraponderali sau obezi. Astfel, boala ficatului steatozic reprezintă o povară atât pentru pacient, cât și pentru întreaga societate, care impune necesitatea screeningului și a diagnosticului timpuriu.

Referințe

1. Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G, Romero-Gomez, M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. In: Journal of Hepatology, 2020, vol. 73, 202-209. https://doi.org/10.1016/j.jhep.2020.07.045

2. Velarde-Ruiz Velasco, J.A., García-Jiménez, E.S., García-Zermeño, K.R. et al. Extrahepatic complications of non-alcoholic fatty liver disease. In: Rev. Gastroenterol México (English Ed.), 2019, no. 84 (4), 472-481. https://doi.org/10.1016/j.rgmxen.2019.05.004

3. Quek, J., Ng, C.H., Tang, A., Chew, N., Chan, M., Khoo, C.M,. et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. In: Endocr. Pract., 2022, no. 28 (7), 667-672. https://doi.org/10.1016/j.eprac.2022.03.016

4. Lazarus, J.V., Mark, H.E., Anstee, Q.M., Arab, J.P., Batterham, R.L., Castera, L. et al. Advancing the global public health agenda for NAFLD: a consensus statement. In: Nat Rev. Gastroenterol Hepatol. 2022, no. 19(1), 60-78.

5. Abd El-Kader, S., El-Den, Ashmawy E. Non-alcoholic fatty liver disease: The diagnosis and management. In: World J Hepatol. 2015, no. 7 (6), 846-858. https://doi.org/10.4254/wjh.v7.i6.846

6. Ng, C.H., Huang, D.Q., Nguyen, M.H.. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. In: Clin Mol Hepatol. 2022, no. 28 (4), 790-801. https://doi.org/10.3350/cmh.2022.0070

7. Blomdahl, J., Nasr, P., Ekstedt, M., Kechagias, S. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. In: Metabolism Clinical and Experimental, 2020, vol. 115, 1-5. https://doi.org/10.1016/j.metabol.2020.154439

8. Fouad, Y., Waked, I., Bollipo, S., Gomaa, A., Ajlouni, Y., Attia, D.. What's in a name? Renaming 'NAFLD' to 'MAFLD'. In: Liver International, 2020, vol. 40, 1254-1261. https://doi.org/10.1111/liv.14478

9. Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. In: Hepatology, 2023, no. 78(6), 1966-1986.

10. Allen, A.M., Therneau, T.M., Larson, J.J., Coward, A., Somers, V.K., Kamath P.S. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. In: Hepatology, 2018, no. 67(5), 1726-1736. https://doi.org/10.1002/hep.29546

11. Huh, Y., Cho, Y.J., Nam, G.E. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. In: J. Obes Metab Syndr., 2022, no. 31(1), 17-27, https://doi.org/10.7570/jomes22021

12. Perumpail, B.J., Khan, M.A., Yoo, E.R., Cholankeril, G., Kim, D., Ahmed, A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. In: World J Gastroenterol, 2017, no. 23(47), 8263-8276, https://doi.org/10.3748/wjg.v23.i47.8263

13. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. In: Hepatology, 2016, no. 64(1), 73-84, https://doi.org/10.1002/hep.28431

14. Abdel-Rahman, R. Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. In: Asian Pac J Trop Biomed., 2022, no. 12(3), 99-114, https://doi.org/10.4103/2221-1691.338919

15. Paik, J.M., Golabi, P., Younossi, Y., Mishra, A., Younossi, Z.M. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. In: Hepatology, 2020, no. 72(5), 1605-1616, https://doi.org/10.1002/hep.31173

16. Watt, M.J., Miotto, P.M., De Nardo, W., Montgomery

M.K. The Liver as an Endocrine Organ - Linking NAFLD and Insulin Resistance. In: Endocr Rev., 2019, no. 40(5), 1367-1393, https://doi.org/10.1210/er.2019-00034

17. Yu, C., Wang, M., Zheng, S., Xia, M., Yang, H., Zhang, D., et al. Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. In: J Clin Transl Hepatol., 2022, no.10(1), 6-16, https://doi.org/10.14218/JCTH.2021.00089

18. Wong, R.J., Cheung, R. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018. In: Clin Gastroenterol Hepatol., 2022, no. 20(3), 610-613, https://doi.org/10.1016/j.cgh.2021.01.030

19. Chan, K.E., Koh, T., Tang, A., Quek, J., Yong, J., Tay, P., et al. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A meta-analysis and systematic review of 10 739 607 individuals. In: J Clin Endocrinol Metab., 2022, no. 107(9), 2691-2700, https://doi.org/10.1210/clinem/dgac321

20. Kim, D., Kim, W., Kim, H., Therneau, T. Association Between Noninvasive Fibrosis Markers and Mortality Among Adults With Nonalcoholic Fatty Liver Disease in the United States. In: Hepatology, 2013, vol. 57(4), 1357-1365. https://doi.org/10.1002/hep.26156

21. Noureddin, M., Ntanios, F., Malhotra, D., Hoover, K., Emir, B., McLeod, E., et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. In: Hepatol Commun., 2022, 1-12, https://doi.org/10.1002/hep4.1935

22. Kallwitz, E., Daviglus, M., Allison, M., Emory, K., Zhao, L., Kuniholm, M., et al. Prevalence of Suspected Non-alcoholic Fatty Liver Disease in Hispanic/Latino Individuals Differs by Heritage. In: Clinical Gastroenterology and Hepatology, 2015, vol. 13 (3), 569-576, https://doi.org/10.1016/j.cgh.2014.08.037

23. Vidal-Cevallos, P., Torre, A., Mendez-Sanchez, N., Uribe, M., Chavez-Tapia, N.. Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. In: Clin Liver Dis., 2022, no. 19(2), 68-72, https://doi.org/10.1002/cld.1167

24. Alswat, K., Aljumah, A., Sanai, F., Abaalkhail, F., Alghamdi, M., Al Hamoudi, W., et al. Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. In: Saudi J Gastroenterol, 2018, 24(4), 211-219, https://doi.org/10.4103/sjg.SJG_122_18

25. Zhou, J., Zhou, F., Wang, W., Zhang, X., Ji, Y., Zhang, P., et al. Epidemiological features of NAFLD from 1999 to 2018 in China. In: Hepatology. John Wiley and Sons Inc, 2020, vol. 71, 1851-1864, https://doi.org/10.1002/hep.31150

26. Lee, H., Kim, B., Kim, S., Park, J., Kim, D., Ahn, S., et al. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. In: Dig Dis Sci. 2017, no. 62(8), 2150-2158, https://doi.org/10.1007/s10620-017-4592-0

27. Caballería, L., Pera, G., Arteaga, I., Rodríguez, L., Alumà, A., Morillas, R., et al. High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study. In: Clin Gastroenterol Hepatol. 2018, no. 16(7), 1138-1145, https://doi.org/10.1016/j.cgh.2017.12.048

28. Llop, E., Iruzubieta, P., Perelló, C., Fernández Carrillo, C., Cabezas, J., Escudero, M., et al. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. In: United Eur Gastroenterol J. 2021, no. 9(8), 892-902, https://doi.org/10.1002/ueg2.12109

29. Crespo, J., Iruzubieta, P., Lazarus, J. Can NAFLD overwhelm the Spanish healthcare system in the years to come? In: Rev Esp Enfermedades Dig., 2022, no. 114(1), 5-9.

30. Cholongitas, E., Pavlopoulou, I., Papatheodoridi, M., Markakis, G., Bouras, E., Haidich, A., et al. Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis. In: Ann Gastroenterol., 2021, no. 34(3), 404-414 ,https://doi.org/10.20524/aog.2021.0604

31. Peltec A., Ivanov V., Toaca I., Matcovschii S. Cardiovascular risk profile in patients with hepatic steatosis. In: Mold J Heal Sci., 2022, no. 27(1), 17-31, https://doi.org/10.52645/MJHS.2022.1.02

32. Lupașco, I., Dumbrava, V-T, Harea, G., Tocan, A., Ursachii, C., Cebanu, E., et al. Sindromul metabolic și steatoza hepatică. In: Sănătate publică, Econ și Manag în Med., 2016, no. 4 (68), 60-65.

33. Lonardo, A., Suzuki, A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research, In: J Clin Med, 2020, vol 9, 1-29, https://doi.org/10.3390/jcm9051278

34. DiStefano, J. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. In: Endocrinology, 2020, vol. 161(10), 1-12, https://doi.org/10.1210/endocr/bqaa134

35. Anderson, E., Howe, L., Jones, H., Higgins, J., Lawlor D., Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. In: Plos One, 2015, no. 10, 1-14, https://doi.org/10.1371/journal.pone.0140908

36. Alfani, R., Vassallo, E. Pediatric Fatty Liver and Obesity: Not always justa matter of non-alcoholic fatty liver disease. In: Children (Basel), 2018, no. 5(12), 1-13, https://doi.org/10.3390/children5120169

37. Neri, C., Scapaticci, S., Chiarelli, F., Giannini, C. Liver Steatosis: a marker of metabolic risk in children. In: Int J Mol Sci., 2022, vol. 23(9), 2-32, https://doi.org/10.3390/ijms23094822

38. Liu, J., Mu, C., Li, K., Luo, H., Liu, Y., Li, Z. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. In: Int J Public Health, 2021, no. 66, 1-9, https://doi.org/10.3389/ijph.2021.1604371

39. Lin, G., Xinhe, Z., Haoyu, T., Xing, J., Dan, L., Ningning, W., et al. Epidemiology and lifestyle survey of non-alcoholic fatty liver disease in school-age children and adolescents in Shenyang, Liaoning. In: BMC Pediatr., 2022, vol. 22(1), 1-9, https://doi.org/10.1186/s12887-022-03351-w

40. Li, L., Liu, D., Yan, H., Wang, Z., Zhao, S., Wang, B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. In: Obes Rev., 2016, no. 17(6), 510-519, https://doi.org/10.1111/obr.12407

41. Dai, W., Ye, L., Liu, A., Wen, S., Deng, J., Wu, X., et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. In: Med (United States), 2017, vol. 96(39), 1-8, https://doi.org/10.1097/MD.0000000000008179

42. Rhee, E.J. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. In: Endocrinol Metab. 2019, vol. 34(3), 226-233, https://doi.org/10.3803/EnM.2019.34.3.226

43. Koutny, F., Weghuber, D., Bollow, E., Greber-Platzer, S., Hartmann, K., Körner, A, et al. Prevalence of prediabetes and type 2 diabetes in children with obesity and increased transaminases in European German-speaking countries. Analysis of the APV initiative. In: Pediatr Obes. 2020, no. 15(4), 1-8, https://doi.org/10.1111/ijpo.12601

44. Tomah, S., Alkhouri, N., Hamdy, O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? In: Clin. Diabetes Endocrinol., 2020, vol. 6(1), 1-11, https://doi.org/10.1186/s40842-020-00097-1

45. Zeng, J., Qin, L., Jin, Q., Yang, R., Ning, G., Su, Q., et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. In: Hepatobiliary Pancreat Dis Int., 2022, no. 21(2), 154-161, https://doi.org/10.1016/j.hbpd.2022.01.006

46. Valenti, L., Bugianesi, E., Pajvani, U., Targher, G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? In: Liver Int., 2016, no. 36(11), 1563-1579, https://doi.org/10.1111/liv.13185

47. Hazlehurst, J., Woods, C., Marjot, T., Cobbold, J., Tomlinson J. Non-alcoholic fatty liver disease and diabetes. In: Metabolism, 2016, no. 65(8), 1096-1108, https://doi.org/10.1016/j.metabol.2016.01.001

48. Allen, A.M., Lazarus, J., Younossi, Z. Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. In: J Hepatol., 2023, nr. 79(1), 209-217, https://doi.org/10.1016/j.jhep.2023.01.026

49. Lam, B., Kurzke, K., Younossi, Z. The clinical and economic burden of nonalcoholic steatohepatitis. In: Current Hepatology Reports. Springer. 2018, vol. 17, no. 4, 345-349, https://doi.org/10.1007/s11901-018-0423-9

50. Witkowski, M. et al. The economic burden of non-alcoholic steatohepatitis: a systematic review. In: PharmacoEconomics, 2022, vol. 40, no. 8, 751-776, https://doi.org/10.1007/s40273-022-01140-y

51. O'Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. In: JHEP reports : innovation in hepatology, 2020, vol. 2, no. 5, 1-9, https://doi.org/10.1016/j.jhepr.2020.100142

52. Cotter, T.G. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. In: Journal of Gastroenterology. Springer. 2020, vol. 55, no. 7, 722-730, https://doi.org/10.1007/s00535-020-01684-w

53. Wong, R.J. et al. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. In: Journal of Clinical Gastroenterology. Lippincott Williams and Wilkins, 2021, vol. 55, no. 10, 891-902, https://doi.org/10.1097/MCG.0000000000001409